The preliminary results of phase 2 TRITON2 study was recently presented at the 2018 ESMO Congress. In this study, metastatic castration-resistant prostate cancer patients carrying an alteration in BRCA1, BRCA2, ATM, or other homologous recombination repair (HRR) genes were assigned to receive rucaparib. Within the enrolled evaluable patients, 45 peoples (52.9%) had a BRCA1/2 mutation, 18 (21.2%) had an ATM mutation, 13 (15.3%) had a CDK12 mutation, and 9 (10.6%) had other non-BRCA HRR mutations. The confirmed PSA response rate was 51.1% in BRCA1/2 mutation group, 0% in ATM mutation group, 7.7% in CDK12 mutation group, and 22.2% in patients with other non-BRCA HRR mutations. Although the enrollment of TRITON2 is ongoing, the preliminary results demonstrated that rucaparib may be a promising treatment option for metastatic castration-resistant prostate cancer patients with a BRCA1/2 mutation.
Source : Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284